Given the fact that bevacizumab and regorafenib are both approved for patients with metastatic CRC, we tested SC-78 in combination with 5-FU, in comparison with bevacizumab plus 5-FU, on effects of anti-migration in a panel of CRC cell lines to further support our findings of SC-78 as an effective SHP-1 agonist targeting STAT3/VEGF-A inhibition (Supplement Figure S3). Here, VEGFA is linked to colorectal carcinoma.